Comparison of Four Methods for Determining Lysostaphin Susceptibility of Various Strains of Staphylococcus aureus

Por Kusuma, Caroline M., Kokai-Kun, John F.
Publicado em 2005

Lysostaphin-Resistant Variants of Staphylococcus aureus Demonstrate Reduced Fitness In Vitro and In Vivo

Por Kusuma, Caroline, Jadanova, Anna, Chanturiya, Tanya, Kokai-Kun, John F.
Publicado em 2007

Characterization of Membrane-Associated Clostridium perfringens Enterotoxin following Pronase Treatment

Por Wieckowski, Eva U., Kokai-Kun, John F., McClane, Bruce A.
Publicado em 1998

In Vitro Activity of Recombinant Lysostaphin against Staphylococcus aureus Isolates from Anterior Nares and Blood

Por von Eiff, Christof, Kokai-Kun, John F., Becker, Karsten, Peters, Georg
Publicado em 2003

Lysostaphin Cream Eradicates Staphylococcus aureus Nasal Colonization in a Cotton Rat Model

Por Kokai-Kun, John F., Walsh, Scott M., Chanturiya, Tanya, Mond, James J.
Publicado em 2003

Lysostaphin Disrupts Staphylococcus aureus and Staphylococcus epidermidis Biofilms on Artificial Surfaces

Por Wu, Julie A., Kusuma, Caroline, Mond, James J., Kokai-Kun, John F.
Publicado em 2003

Identification of a Clostridium perfringens Enterotoxin Region Required for Large Complex Formation and Cytotoxicity by Random Mutagenesis

Por Kokai-Kun, John F., Benton, Kimberly, Wieckowski, Eva U., McClane, Bruce A.
Publicado em 1999

Antibody against the Carboxyl Terminus of Intimin α Reduces Enteropathogenic Escherichia coli Adherence to Tissue Culture Cells and Subsequent Induction of Actin Polymerization

Por Carvalho, Humberto M., Teel, Louise D., Kokai-Kun, John F., O'Brien, Alison D.
Publicado em 2005

Catalase (KatA) and Alkyl Hydroperoxide Reductase (AhpC) Have Compensatory Roles in Peroxide Stress Resistance and Are Required for Survival, Persistence, and Nasal Colonization in...

Por Cosgrove, Kate, Coutts, Graham, Jonsson, Ing-Marie, Tarkowski, Andrej, Kokai-Kun, John F., Mond, James J., Foster, Simon J.
Publicado em 2007

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

Por Kokai-Kun, John F., Roberts, Tracey, Coughlin, Olivia, Sicard, Eric, Rufiange, Marianne, Fedorak, Richard, Carter, Christian, Adams, Marijke H., Longstreth, James, Whalen, Heidi, Sliman, Joseph
Publicado no Antimicrob Agents Chemother (2017)

Characterization of IsaA and SceD, Two Putative Lytic Transglycosylases of Staphylococcus aureus

Por Stapleton, Melanie R., Horsburgh, Malcolm J., Hayhurst, Emma J., Wright, Lynda, Jonsson, Ing-Marie, Tarkowski, Andrej, Kokai-Kun, John F., Mond, James J., Foster, Simon J.
Publicado em 2007

Phase 1/2 Double-Blind, Placebo-Controlled, Dose Escalation, Safety, and Pharmacokinetic Study of Pagibaximab (BSYX-A110), an Antistaphylococcal Monoclonal Antibody for the Prevent...

Por Weisman, Leonard E., Thackray, Helen M., Garcia-Prats, Joseph A., Nesin, Mirjana, Schneider, Joseph H., Fretz, Jennifer, Kokai-Kun, John F., Mond, James J., Kramer, William G., Fischer, Gerald W.
Publicado em 2009